Details

Autor(en) / Beteiligte

• Deuschl, Günther
• Schade-Brittinger, Carmen
• Krack, Paul
• Volkmann, Jens
• Schäfer, Helmut
• Bötzel, Kai
• Daniels, Christine
• Deutschländer, Angela
• Dillmann, Ulrich
• Eisner, Wilhelm
• Gruber, Doreen
• Hamel, Wolfgang
• Herzog, Jan
• Hilker, Rüdiger
• Klebe, Stephan
• Kloß, Manja
• Koy, Jan
• Krause, Martin
• Kupsch, Andreas
• Lorenz, Delia
• Lorenzl, Stefan
• Mehdorn, H. Maximilian
• Moringlane, Jean Richard
• Oertel, Wolfgang
• Pinsker, Marcus O
• Reichmann, Heinz
• Reuß, Alexander
• Schneider, Gerd-Helge
• Schnitzler, Alfons
• Steude, Ulrich
• Sturm, Volker
• Timmermann, Lars
• Tronnier, Volker
• Trottenberg, Thomas
• Wojtecki, Lars
• Wolf, Elisabeth
• Poewe, Werner
• Voges, Jürgen

Titel

A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease

Ist Teil von

• The New England journal of medicine, 2006-08, Vol.355 (9), p.896-908

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2006

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this randomized trial comparing neurostimulation of the subthalamic nucleus with medical management alone in 156 patients with severe Parkinson's disease, neurostimulation improved the quality of life and motor symptoms. Severe adverse events included a fatal intracerebral hemorrhage resulting from surgical placement of the neurostimulator. In patients with severe Parkinson's disease, neurostimulation improved the quality of life and motor symptoms. Severe adverse events included a fatal intracerebral hemorrhage resulting from surgical placement of the neurostimulator. Parkinson's disease is one of the most disabling chronic neurologic diseases and leads to a significant loss of quality of life. 1 , 2 Several drugs are available that can effectively treat the symptoms of the disease, but long-term medical management is often complicated by the appearance of levodopa-induced motor complications, leading to rapid changes between periods of severe akinesia and periods of mobility that may be accompanied by troublesome hyperkinesias. 3 Dopamine agonists, amantadine, catechol O -methyltransferase (COMT) inhibitors, 3 and other drugs can effectively improve mobility and reduce dyskinesias initially but typically fail after several years. 4 The administration of high-frequency continuous electrical . . .